Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Apararenone is a non-steroidal mineralocorticoid receptor antagonist (Ki = 0.104 µM for the human receptor).1 It is selective for mineralocorticoid receptors over estrogen receptor α (ERα) and ERβ and glucocorticoid, progesterone, and androgen receptors (IC50s = >100 µM for all). Apararenone increases the urinary ratio of sodium to potassium in adrenalectomized rats in a dose-dependent manner. It inhibits aldosterone- and nephrectomy-induced increases in systolic blood pressure and urinary albumin levels, as well as myocardial necrosis and fibrosis, cardiac arterial degeneration, and renal tubule damage, in a rat model of renal hypertension when administered at doses of 3 or 10 mg/kg per day.
WARNING This product is not for human or veterinary use.
1. Discovery of apararenone (MT-